DIAGNOSIS AND/OR PROGNOSIS OF HER2+ CANCER USING ONE OR MORE MIRNA AS BIOMARKERS

About 25% of primary human breast cancers are due to the deregulated expression of ErbB2/HER2. HER2-targeted therapies have improved patient survival, but both de novo and acquired resistance remain a challenge, as only 25% of treated patients respond to the current therapies. Equivocal HER2 status also remains an issue as it affects subsequent clinical management. Following the analysis of the expression level of more than 800 miRNA in several human breast cancer cells and patient biopsies with various HER2+ status, the team has identified novel miRNA biomarkers for the diagnosis and prognosis of HER2+ cancers. This allows for further stratification of patients and offers new therapeutic strategies based on the modulation of some of these miRNA. The team has the expertise and know-how required to measure miRNA and HER2 expression levels in biological samples as well as to assess HER2 activation status, downstream signaling and functional effects on cell proliferation and survival in breast cancer.

Applications

• Diagnosis of HER2+ breast cancer
• Evaluation of the prognosis of HER2+ breast cancer patients
• Novel HER2-targeted therapy based on miRNA modulation

Competitive advantages

• New biomarkers to stratify breast cancer patients with equivocal HER2+ status (4-12% cases)
• New biomarkers to evaluate HER2+ breast cancer prognosis
• MiRNAs expression level assessed with non-invasive techniques

Intellectual property

WO2019081610A1; EP, US & JP

Keywords

ERBB2 - HER2+ breast cancers - Patients stratification - MiRNA Diagnostic/prognostic - Biomarkers Equivocal HER2 status